Logistics startup GetSwift has confirmed it will fight an appeal to the High Court by law firm Squire Patton Boggs challenging a landmark ruling that permanently stayed two of three competing shareholder class actions against the company.
Visa has resolved a lawsuit by a fintech founder alleging it misused its market power by banning the use of dynamic currency conversion services in several countries, including Australia and the US.
A judge has signed off on a $16.4 million settlement of a class action against Cash Converters, but not before scrapping a clause he said tied the court’s hands by making the deal conditional on the appointment of Maurice Blackburn as scheme administrator.
Generic drug maker Sun Pharma has emerged victorious in a lawsuit brought against it by Mylan relating to Sun’s plans to launch a generic version of cholesterol drug fenofibrate.
An Australian partner of international law firm Jones Day has moved to the firm’s Singapore office to bolster its growing team of international arbitration specialists.
Businessman Clive Palmer has successfully registered the United Australia Party name with the corporate regulator in what appears to be a settlement of his trade mark infringment suit against the expelled directors of another political party who had adopted the coveted moniker two years ago.
We Buy Houses’ director Rick Otton has withdrawn his appeal of a ruling that slugged him with a $6 million fine for misleading property investors, the highest ever penalty imposed on an individual for breaches of the Australian Consumer Law.
AIG Australia has appealed a decision that found it’s liable for covering four former directors being sued by collapsed Kaboko Mining after a failure to repay a US$5.95 million loan allegedly led to the company’s insolvency.
ASIC has been ordered to reveal the extent of its communications with experts that are compiling a report central to its case against AMP over alleged insurance churning by one of its former financial advisers.
Denmark-based Lundbeck cannot recover damages for the alleged infringement of its Lexapro patent by generic drug companies that it dropped its claims against, a judge has found.